Rising rates of breast cancer among working-age Australian women have prompted urgent calls for action to address the growing impact of financial ...
A controversial blood test that promises to detect multiple cancers in their early stages failed to meet a key trial endpoint of a significant reduction in stage III-IV cases. Investors in the US ...
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Itovebi® (inavolisib) is the first breast cancer therapy ...
The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...
Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes. The National Comprehensive Cancer Network (NCCN) ...
This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
For our second evaluation of braiding hair, CR tested 30 human and synthetic hair products to determine if there are less ...
RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug ...
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be ...
Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities. | In a Worker Adjustment and Retraining Notification Act alert filed this ...
VORANIGO (R) was approved by Health Canada in August 2024 for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation in adults and pediatric patients aged ...
Q4 2025 Press Conference Call February 26, 2026 5:00 AM ESTCompany ParticipantsZiad GebranThomas Buberl - CEO & DirectorGuillaume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results